UK markets closed

BNTX Dec 2024 105.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
10.400.00 (0.00%)
At close: 01:05PM EDT
Full screen
Previous close10.40
Open11.15
Bid5.50
Ask6.60
Strike105.00
Expiry date2024-12-20
Day's range10.40 - 11.15
Contract rangeN/A
Volume93
Open interest1.02k
  • Yahoo Finance Video

    FDA considers updating COVID boosters, Novavax stock reacts

    The US Food and Drug Administration (FDA) is set to vote on recommendations for updated COVID-19 booster shots as the KP.2 variant strain begins to spread across the US. Yahoo Finance Health Reporter Anjalee Khemlani joins Market Domination to discuss the impact this is having on vaccine makers, particularly Novavax (NVAX), whose stock has shot up in Monday's session. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Luke Carberry Mogan.

  • Globe Newswire

    Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

    Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic non-small cell lung cancer treated with a combination of acasunlimab and pembrolizumab every six weeksData from this ongoing Phase 2 study to inform the planned pivotal Phase 3 trial, which is expected to start before the end of 2024 COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 — Genmab A/S (

  • GlobeNewswire

    BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

    BioNTech and CEPI aim to enhance local R&D, clinical and commercial-scale manufacturing capacities to develop potential mRNA vaccines in Africa, for AfricaCEPI to fund up to $145 million to support BioNTech in broadening the scope of the manufacturing facility in Kigali, Rwanda, aimed at addressing needs of African countries and in compliance with global standards Partnership intends to contribute to building a sustainable and resilient end-to-end African vaccine ecosystemBioNTech and CEPI commi